Cyclopharm Limited provided revenue guidance for the six months ended June 30, 2020. The company anticipates sales revenue for the six months will be approximately $5.6 million (versus $6.5 million in first half of 2019). Revenue for the period was impacted by factors relating to the COVID-19 pandemic and a consequential deferral of Patient Administration Set (PAS) consumable orders from predominantly a delay in the scheduled late Second Quarter France order and generally lower PAS volumes in most markets.